Here you can find the latest TOPADUR news & events.
The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.
EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.
TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.
TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.
TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.
TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.
Do you need more information or references? Media contact